Cliquez pour voir le graph
Cliquez pour voir la ligne de temps
Ligne de temps
Humoral immune response & immunotherapy in HBV infection
Hugo Mouquet (PI)
Human infections caused by hepatitis B virus (HBV) are major healthcare issues. Despite available effective vaccines, more than 250 million individuals worldwide are chronically infected by HBV, which accounts for approximately 1 million deaths […]
2022An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa., Mol Ther 2022 Apr; (): .
2021A virus-derived microRNA targets immune response genes during SARS-CoV-2 infection, EMBO Reports (2021)e54341.
2021A virus-derived microRNA targets immune response genes during SARS-CoV-2 infection., EMBO Rep 2021 Dec; (): e54341.
2021Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice., EMBO Mol Med 2021 12; 13(12): e14459.
2020Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models., Cell Host Microbe 2021 Feb 10;29(2):236-249: .
2020Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers., J. Exp. Med. 2020 ; 217(10): .
2015Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes, Vaccine 2015 Aug;33(36):4548-53.
2014Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?, Med. Microbiol. Immunol. 2015 Feb;204(1):121-9.
2014TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice, Gut 2014 Nov;.
2014Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection, PLoS ONE 2014;9(3):e92140.
+Voir la liste complète de publications